Tenaya Therapeutics (TNYA)’ treatment of Duchenne muscular dystrophy was granted FDA orphan designation status, according to a post to the agency’s website.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Tenaya’s TN-401: Differentiated PKP2 Gene Therapy Opportunity Underpins Favorable Risk–Reward and Buy Rating
- Advancing Pipeline and Regulatory Clarity Underpin Buy Rating on Tenaya Therapeutics
- Tenaya Therapeutics: Early Gene Therapy Promise, Cash Runway to 2H27, and 2026 Data Catalysts Support Buy Rating and $5 Target
- Tenaya Therapeutics: Gene Therapy Momentum and De‑Risking Clinical Milestones Support Buy Rating
- Tenaya Therapeutics reports Q4 EPS (12c), consensus (12c)